Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.15 -4.6%	$0.61	$0.40 ▼ $2.42	$61.32M	1.14	868,175 shs	507,869 shs
ANVS Annovis Bio	$2.34 -0.6%	$2.60	$1.11 ▼ $10.54	$45.41M	1.51	445,789 shs	71,377 shs
TIL Instil Bio	$27.52 -1.7%	$26.56	$10.80 ▼ $92.00	$185.67M	2.16	190,048 shs	60,448 shs
TNYA Tenaya Therapeutics	$1.12 +1.5%	$0.79	$0.36 ▼ $4.01	$183.35M	3.01	2.96 million shs	2.64 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+9.09%	+44.23%	+91.69%	+156.85%	-51.81%
ANVS Annovis Bio	-2.87%	-5.20%	-19.39%	-1.25%	-74.04%
TIL Instil Bio	-1.44%	+10.54%	-5.69%	-7.74%	+118.58%
TNYA Tenaya Therapeutics	+1.85%	-11.29%	+41.04%	+147.52%	-59.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.2051 of 5 stars	3.4	1.0	2.8	4.2	1.3
ANVS Annovis Bio	1.9753 of 5 stars	3.3	3.0	0.6	1.7	0.6
TIL Instil Bio	3.6119 of 5 stars	3.5	4.0	3.3	3.3	0.6
TNYA Tenaya Therapeutics	2.9471 of 5 stars	3.5	1.0	2.7	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	188.21% Upside
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	670.88% Upside
TIL Instil Bio	3.00	Buy	$119.00	332.35% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	460.04% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, TNYA, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/27/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/15/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$1.20 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.94 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$19.50 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.20	N/A	N/A	N/A	N/A	-115.67%	-84.82%	11/6/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.04	N/A	N/A	N/A	N/A	-206.01%	-158.26%	11/14/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$12.92	N/A	N/A	N/A	N/A	-54.32%	-33.65%	11/12/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$0.96	N/A	N/A	N/A	N/A	-93.83%	-75.66%	11/5/2025 (Estimated)

Latest ANVS, ALXO, TNYA, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TIL Instil Bio	-$1.72	-$3.24	-$1.52	-$3.24	N/A	N/A
8/12/2025	Q2 2025	ALXO ALX Oncology	-$0.46	-$0.49	-$0.03	-$0.49	N/A	N/A
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
8/6/2025	Q2 2025	TNYA Tenaya Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.11	4.52	4.52
ANVS Annovis Bio	N/A	7.65	7.65
TIL Instil Bio	0.64	14.97	14.97
TNYA Tenaya Therapeutics	N/A	6.00	6.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
TIL Instil Bio	60.56%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
ANVS Annovis Bio	20.80%
TIL Instil Bio	47.20%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.55 million	42.31 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
TIL Instil Bio	410	6.75 million	3.57 million	No Data
TNYA Tenaya Therapeutics	110	162.98 million	83.69 million	Optionable

ANVS, ALXO, TNYA, and TIL Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from Analysts

August 28 at 3:10 AM | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from Brokerages

August 26 at 3:15 AM | americanbankingnews.com

Faraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

August 20, 2025 | marketbeat.com

Tenaya Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | tipranks.com

What is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?

August 11, 2025 | marketbeat.com

Q3 EPS Estimate for Tenaya Therapeutics Lifted by Analyst

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Hold

August 10, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan Capital

August 8, 2025 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025 | globenewswire.com

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

August 7, 2025 | msn.com

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Tenaya (TNYA) Q2 Loss Narrows 59%

August 7, 2025 | fool.com

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Equities Analysts Offer Predictions for TNYA Q1 Earnings

August 4, 2025 | marketbeat.com

Lifesci Capital Issues Negative Outlook for TNYA Earnings

August 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from Analysts

August 1, 2025 | marketbeat.com

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies

July 30, 2025 | investing.com

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025 | globenewswire.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, TNYA, and TIL Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.14 -0.06 (-4.58%)

As of 03:41 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$2.34 -0.02 (-0.64%)

As of 03:41 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Instil Bio NASDAQ:TIL

$27.52 -0.48 (-1.70%)

As of 03:40 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tenaya Therapeutics NASDAQ:TNYA

$1.12 +0.02 (+1.45%)

As of 03:41 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time